Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.2K
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

203
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
203
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

299
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
299
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

196
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
196
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.

Cancer·2026
Same author

Quantitative bias analyses to address measurement error in time-to-event endpoints.

American journal of epidemiology·2026
Same author

Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Cancer immunology research·2026
Same author

Body Composition Metrics Associated with Time to Progression in Smoldering Multiple Myeloma.

Diagnostics (Basel, Switzerland)·2025
Same author

Transdifferentiation From Multiple Myeloma to Myeloid Sarcoma in the Setting of CAR T-Cell Therapy.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy.

British journal of haematology·2025

Related Experiment Video

Updated: Jan 9, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K

Choosing the optimal maintenance strategy in multiple myeloma.

Benjamin Puliafito1, Diana Cirstea1, Noopur Raje1

  • 1Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA.

Hematology. American Society of Hematology. Education Program
|December 5, 2025
PubMed
Summary

Maintenance strategies for multiple myeloma are evolving beyond lenalidomide. Novel approaches, including proteasome inhibitors and anti-CD38 monoclonal antibodies (mAbs), offer enhanced benefits, especially for high-risk patients.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.4K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.0K

Related Experiment Videos

Last Updated: Jan 9, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.4K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.0K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Lenalidomide is the standard maintenance therapy post-autologous stem cell transplant for multiple myeloma.
  • High-risk multiple myeloma patients may benefit from risk-adapted maintenance strategies.
  • Anti-CD38 monoclonal antibodies (mAbs) are increasingly used in induction and consolidation therapy.

Purpose of the Study:

  • To review the evolving landscape of maintenance strategies in multiple myeloma.
  • To explore the role of proteasome inhibitors and anti-CD38 mAbs in maintenance therapy.
  • To discuss future directions including immunotherapies and minimal residual disease-guided approaches.

Main Methods:

  • Review of current literature and clinical practices in multiple myeloma maintenance therapy.
  • Analysis of emerging data on novel agents and treatment paradigms.
  • Discussion of ongoing research in immunotherapeutic approaches and MRD-guided strategies.

Main Results:

  • Risk-adapted strategies incorporating proteasome inhibitors show promise for high-risk patients.
  • Anti-CD38 mAbs are being considered for maintenance therapy, altering the treatment paradigm.
  • Novel immunotherapies and minimal residual disease (MRD)-guided strategies are under active investigation.

Conclusions:

  • Maintenance therapy for multiple myeloma is shifting towards more dynamic and personalized approaches.
  • Future strategies aim for more effective and durable responses with potential de-escalation.
  • The integration of novel agents and MRD monitoring will refine future maintenance protocols.